Pfizer

Pfizer's Pricing: Undervalued by 54.9%?

Novo Nordisk

Redwire

Most Active Stocks in Pre-Market Trading: PFE, RDW, UWMC, SMR, NVO, BBAI

Novavax

Novavax Licenses Matrix-M Adjuvant to Pfizer for Upfront Payment of $30 Million and Potential Milestones.

诺瓦瓦克斯医药

Pfizer, Novavax Enter Matrix-M Adjuvant Licensing Agreement

Shionogi to Acquire 11.7% Voting Rights in VIIV HEALTHCARE from GSK and Pfizer

Catalyst<ul> <li>A MACD Golden Cross signal on January 8 suggests potential for a neutral to positive price trend for PFE.</li></ul>Risk<ul> <li>Fund flows show negative outflows across all order sizes, indicating investor caution or pessimism about PFE.</li> <li>Analyst ratings remain neutral with no consensus, reflecting mixed or uncertain expectations about PFE’s future performance.</li> <li>Recent WR Overbought signals indicate a bearish bias, suggesting potential short-term downward pressure on PFE.</li></ul>

Key Factors

Pfizer (PFE) is selling its 11.7% stake in ViiV Healthcare to Shionogi for $1.88 billion to fund a looming revenue decline. Pfizer (PFE) licensed Novavax's Matrix-M adjuvant for $30 million upfront and potential milestones, with Novavax supplying the adjuvant for development. Pfizer (PFE) projects 2026 revenue to fall to a range of $59.5 billion to $62.5 billion, a clear decline from 2024 and projected 2025 sales.

Recent Updates

PFE News